Patents Assigned to NKMAX Co., Ltd.
  • Pharmaceutical composition and methods comprising immune cells and ponatinib
    Patent number: 11504396
    Abstract: Methods and compositions for treating cancer are disclosed. The compositions comprise immune cells pretreated with ponatinib, or immune cells co-administered with ponatinib, where ponatinib promotes survival and anti-cancer cytotoxicity of the immune cells.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 22, 2022
    Assignee: NKMAX Co., Ltd.
    Inventors: Tae-gyun Kim, Yong-hee Rhee, Sang-min Oh
  • Method of producing natural killer cells and composition for treating cancer
    Patent number: 11066644
    Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: July 20, 2021
    Assignee: NKMAX Co., Ltd.
    Inventors: Sang Woo Park, Yong Man Kim, Jae Seob Jung, Yong-Hee Rhee
  • Method of producing natural killer cells and composition for treating cancer
    Patent number: 10590385
    Abstract: A method for producing natural killer cells is disclosed. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from a blood sample; isolating at least one of CD56+ cells and/or CD3?/CD56+ cells from the PBMCs; and co-culturing the at least one of CD56+ cells and/or CD3?/CD56+ cells with a combination of feeder cells in the presence of a cytokine. A composition for treating cancer is also disclosed. The composition comprises the CD56+ natural killer cells produced by the disclosed method and a cytokine.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: March 17, 2020
    Assignee: NKMAX CO., LTD.
    Inventors: Sang Woo Park, Yong Man Kim, Jae Seob Jung, Yong-Hee Rhee
  • Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells
    Patent number: 9938498
    Abstract: The present invention relates to a method for inducing and expanding natural killer cells derived from peripheral blood mononuclear cells, which comprises co-culturing, as feeder cells, irradiated Jurkat cells and irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) cells in the presence of cytokines, along with peripheral blood mononuclear cells. According to the present invention, a large quantity of natural killer cells can be induced and proliferated from a small quantity of peripheral blood mononuclear cells even without the use of high-cost equipment or various kinds of expensive cytokines, thereby making it possible to significantly improve the efficiency and efficacy of the prevention and treatment of cancer using the natural killer cells.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: April 10, 2018
    Assignee: NKMAX Co., Ltd.
    Inventors: Kyung Mi Lee, Seon Ah Lim, Cassian Yee